In the last 50 years, the cure rate for children with cancer has increased from 5–10% to over 80% today. However, this dramatic improvement in outcome has come at a significant cost. Approximately 40% of children suffer irreversible, life-threatening, or long-lasting toxicities that are caused by their medications during cancer treatment. Recent technological advances in genomics have opened the door to potentially identifying genetic differences between individual children that may explain their different responses to cancer therapies. The goals of the emerging field of cancer pharmacogenomics are to identify the genomic factors responsible for individual differences in drug response, specifically drug effectiveness and susceptibility to adverse drug reactions. Pharmacogenomics helps to explain why one child treated with the same medication as another child may respond well to therapy, while another patient may not respond, or worse, may develop a life-threatening adverse drug reaction. The focus of this chapter is to explore recent developments in the pharmacogenomics of pediatric cancer with a focus on serious adverse drug reactions. Specific drugs of focus include thiopurines, methotrexate, cisplatin, vincristine and anthracyclines. Several pharmacogenomic tests are currently available to provide dosing recommendations, and the number of these tests is expected to increase significantly in the future. There is a strong immediate need for international collaboration to advance this research to reduce the occurrence of severe adverse drug reactions in pediatric oncology.
Lammert, M., & Timberlake, E. M. (1986). Termination of foster care for the older adolescent: Issues of emancipation and individuation.
Dou, L., E. Bertrand, C. Cerini, V. Faure, J. Sampol, R. Vanholder, Y. Berland, P. Brunet. ... A. Timberlake, B. Sumpio, R. Pfragner, I. M. Modlin, M. Kidd.
Chendrasekhar A, Moorman DW, Timberlake GA. An evaluation of the effects of ... Chittiboina P, Wylen E, Ogden A, et al. Traumatic spondylolisthesis of the ...
Hartmann LC, Radisky DC, Frost MH, et al. Understanding the premalignant potential of ... D'Alfonso TM, Wang K, Chiu YL, et al. Pathologic upgrade rates on ...
Stensland, J., Speedie, S., Ideker, M., House, J., & Thompson, T. (1999). The relative cost of outpatient ... Deal, J. L. (1987). Appraisal and diagnosis of ...
1 2 Howard, S. and Johnson, B. (2000) Resilient and Non-resilient Behaviour in ... 4 De Haan, L., Hawley, D. and Deal, J. (2002) 'Operationalizing family ...
... are not fluent in the language/s of the medical care provider.72 Research ... Anglo-Americans have traditionally placed a great deal of emphasis on the ...
This practical guide thoroughly discusses both well-established and new interventions that are applied to the spine for the purpose of pain relief.
Several versions of Pearson's MyLab & Mastering products exist for each title, including customized versions for individual schools, and registrations are not transferable.
If a picture paints a thousand words, imagine what video can do? Pearson Medical Assisting Videos help users learn the nuances and the details of many medical assisting procedures.